Mankind Pharma Ltd - 543904 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participant) Regulations, 201803-04-2024
03-04-2024
Mankind Pharma to sell OTC business on a slump-sale basis to yet to be incorporated subsidiary
Mankind Pharma's key OTC products, including ed under its Consumer Healthcare vertical, also include the anti-inflammatory and anti-bacterial product AcneStar, the HealthOk multivitamin tablets, the oral contraceptive brand Unwanted and the antacid Gas-O-Fast02-04-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Acquisition
The Board of Directors of the Company at its meeting held today i.e. April 2, 2024 has inter-alia, considered and approved the Incorporation of a wholly owned subsidiary by the name Mankind Consumer Products Private Limited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs.02-04-2024
Mankind Pharma Ltd - 543904 - Board Meeting Outcome for Outcome Of Board Meeting Held On April 2, 2024
The Board of Directors of the Company at its meeting held today i.e. April 2, 2024, has inter-alia, considered and approved the following: 1. Slump sale of the Over the Counter ('OTC') Business of the Company to Wholly Owned Subsidiary Company proposed to be incorporated with the name of Mankind Consumer Products Private Limited or any other name as approved by Ministry of Corporate Affairs. The transaction will be effective on or before October 1, 2024 or such other date as may be mutually agreed between the parties, subject to customary closing conditions. The Company will continue to have business operations with the proposed incorporated entity on arm's length basis. 2. Incorporation of a wholly owned subsidiary by the name Mankind Consumer Products Private Limited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs.02-04-2024
Mankind Pharma Ltd - 543904 - Closure of Trading Window
Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company''s ''Code of Conduct for prevention of Insider Trading''27-03-2024
Mankind Pharma Ltd - 543904 - Clarification - Increase In Volume
Clarification - Increase in Volume27-03-2024
Mankind Pharma Ltd - 543904 - Clarification sought from Mankind Pharma Ltd
The Exchange has sought clarification from Mankind Pharma Ltd on March 27, 2024, with reference to Movement in Volume. The reply is awaited.27-03-2024
Bulk Deals: Beige share sale drives Mankind Pharma up 2.3%
Shares of Mankind Pharma rose 2.31 percent to Rs 2,265 on NSE27-03-2024
Never follow a leader, be a disruptor'
Home-grown wisdom: Challenger brand strategies from Rajeev Juneja, Vice-Chairman and MD of Mankind Pharma18-03-2024
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of participation in (i) Jefferies Investor Conference at Hong Kong and (ii) meetings with various investors at Singapore14-03-2024